RxDoctor Payments Data

Edward Charbek, MD

Pulmonary Disease · Saint Louis, MONPI 1104113398

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $318,683 of the $372,383 with a category attached, or 85.6%. 13 manufacturers reported payments, led by Sanofi at 49.2% of the total. Among pulmonary disease clinicians in MO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$372,383in general payments, 2019–2025

Across 307 payments — averaging $1212.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi$183K
  • Regeneron Healthcare Solutions, Inc.$135K
  • AstraZeneca$23K
  • Verona Pharma, Inc.$15K
  • Mylan Specialty L.p.$15K
  • Inari Medical, Inc.$181
  • plus $822 from 7 others
$87,633in research payments, 2019–2025

Across 3 payments — averaging $29,211 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AstraZeneca$88K

What the payments were for

  • Consulting fees$11,6883%
  • Speaking & faculty fees$318,68386%
  • Travel & lodging$33,2609%
  • Food & beverage$8,5552%
  • Education$1960%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$372,383 in reported general payments places this provider in the 95th percentile of 295 pulmonary disease providers in Missouri.

See all pulmonary disease providers in Missouri

Medicare billing

Part B allowed, 2024
$59,767
Medicare patients
218
Services billed
534

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Breztri AerosphereBudesonide/Glycopyr/Formoterol27$25,276
Trelegy ElliptaFluticasone/Umeclidin/Vilanter21$18,115
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr21$13,168
Stiolto RespimatTiotropium Br/Olodaterol Hcl18$10,621
Breo ElliptaFluticasone/Vilanterol14$8,488
Bevespi AerosphereGlycopyrrolate/Formoterol Fum16$7,831
SymbicortBudesonide/Formoterol Fumarate13$2,879
Albuterol Sulfate HfaAlbuterol Sulfate76$1,902
Ventolin HfaAlbuterol Sulfate29$1,655
BreynaBudesonide/Formoterol Fumarate11$943
Montelukast Sodium44$287

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$112$39,77156 claims
AstraZenecaBreztri Aerosphere, Bevespi Aerosphere, Symbicort$23,133$35,98556 claims
Boehringer IngelheimStiolto Respimat$91$10,62118 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 295 pulmonary disease providers in Missouri.

Other pulmonary disease in Saint Louis

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →